Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2020-08-21 16:17:19
Reporting Period:
Accepted Time:
2020-08-21 16:17:19
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1498382 Kintara Therapeutics Inc. KTRA Pharmaceutical Preparations (2834) 990360497
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1821508 John Liatos 12707 High Bluff Dr.
Suite 200
San Diego CA 92130
Svp, Business Development Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-08-19 196,750 $0.00 196,750 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
  1. Received in exchange for 125,000 shares of Adgero Biopharmaceuticals Holdings, Inc. ("Adgero") common stock, par value $0.0001 per share, in connection with the completion of the merger (the "Merger"), on August 19, 2020 (the "Effective Date"), of Adgero Acquisition Corp., a subsidiary of the Issuer, with and into Adgero, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 9, 2020. On the Effective Date, each share of Adgero common stock was converted automatically into the right to receive 1.5740 shares of the Issuer's common stock, par value $0.001 per share.